SEPS.F Stock Overview
Focuses on developing diagnostic and therapeutic solutions for the treatment of sepsis. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ASEP Medical Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.04 |
| 52 Week High | CA$0.25 |
| 52 Week Low | CA$0.038 |
| Beta | -2.26 |
| 11 Month Change | -38.46% |
| 3 Month Change | n/a |
| 1 Year Change | -83.67% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| SEPS.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -20.0% | 1.5% | 2.2% |
| 1Y | -83.7% | 20.8% | 31.6% |
Return vs Industry: SEPS.F underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: SEPS.F underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| SEPS.F volatility | |
|---|---|
| SEPS.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SEPS.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SEPS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 6 | Robert E. Hancock | asepmedical.com |
ASEP Medical Holdings Inc., together with its subsidiaries, focuses on developing diagnostic and therapeutic solutions for the treatment of sepsis. It offers peptide technology for therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators, and vaccine adjuvants; diagnostic kits for predicting the onset of severe sepsis and organ failure; and coatings for medical devices. The company was formerly known as Trenchant Life Sciences Investment Corp. and changed its name to ASEP Medical Holdings Inc. in November 2021.
ASEP Medical Holdings Inc. Fundamentals Summary
| SEPS.F fundamental statistics | |
|---|---|
| Market cap | US$2.75m |
| Earnings (TTM) | -US$4.07m |
| Revenue (TTM) | US$120.99k |
22.7x
P/S Ratio-0.7x
P/E RatioIs SEPS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEPS.F income statement (TTM) | |
|---|---|
| Revenue | CA$169.12k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$169.12k |
| Other Expenses | CA$5.86m |
| Earnings | -CA$5.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.074 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,362.99% |
| Debt/Equity Ratio | 1.1% |
How did SEPS.F perform over the long term?
See historical performance and comparison